Azenosertib

FDA granted Fast Track Designation to azenosertib for Cyclin E1 positive ovarian cancer patients, highlighting its potential to address unmet medical needs. Zentalis Pharmaceuticals to share clinical data and regulatory updates on January 29, 2025. Research supports azenosertib's efficacy in Cyclin E1/CDK2 activated tumors.

Zentalis Pharmaceuticals received FDA Fast Track Designation for azenosertib to treat platinum-resistant ovarian cancer. A webcast on January 29, 2025, will present study data, including Phase 2 DENALI and Phase 1b ZN-c3-001 results, and updates on azenosertib's development and regulatory status.

Zentalis Pharmaceuticals received FDA fast-track designation for azenosertib, targeting Cyclin E1-positive platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer patients, aiming to address high unmet medical needs and poor outcomes associated with chemotherapy resistance.

Zentalis Pharmaceuticals will host a webcast on January 29, 2025, to present azenosertib study data, including Phase 2 DENALI and Phase 1b ZN-c3-001 trial results, and updates on azenosertib's development and regulatory path. Azenosertib, a WEE1 inhibitor, shows promise in treating various cancers by enabling cell cycle progression despite DNA damage.

Zentalis Pharmaceuticals received FDA Fast Track Designation for azenosertib, targeting Cyclin E1 positive ovarian cancer patients, highlighting its potential to address unmet medical needs. A corporate event on January 29, 2025, will update on azenosertib's clinical data and regulatory path. Research in npj Precision Oncology supports azenosertib's sensitivity in Cyclin E1/CDK2 activated models.

FDA grants Fast Track Designation to azenosertib for Cyclin E1 positive ovarian cancer patients, highlighting its potential to address unmet medical needs. Zentalis to present azenosertib clinical data and regulatory updates on January 29, 2025. Research in npj Precision Oncology supports Cyclin E1/CDK2 activation as a predictor of azenosertib sensitivity.

Azenosertib, synthesized by Zentalis Pharmaceuticals, was tested on various human cancer cell lines for cell viability and proliferation. Techniques included cell proliferation assays, Jess Simple Western analysis, generation of stable cell lines, siRNA knockdown, DNA fiber assays, immunofluorescence, immunohistochemistry, high-content imaging, and in vivo studies. Statistical analysis used GraphPad Prism, with clinical trials conducted under U.S. ethical guidelines.

Zentalis Pharmaceuticals focuses on developing azenosertib, a WEE1 inhibitor for advanced solid tumors, showing promise in clinical trials. The company explores genomic instability in tumors and advances research on protein degraders, aiming for azenosertib to be first-in-class and best-in-class.

The FDA lifted a partial clinical hold on Zentalis Pharmaceuticals’ azenosertib, enabling continued cancer treatment evaluation. Zentalis’ stock rose 53% post-decision. Azenosertib, targeting WEE1 protein, showed promise in Phase Ib trials for ovarian cancer. Zentalis plans to present monotherapy data in 2024.

Zentalis Pharmaceuticals announces FDA removal of partial clinical hold on azenosertib studies, allowing resumption of patient enrollment. Azenosertib, an orally bioavailable WEE1 inhibitor, targets gynecologic malignancies and is being evaluated in ovarian cancer and other tumor types. Zentalis plans to present monotherapy data and expects to meet 2024 data guidance. The company remains focused on advancing azenosertib and exploring protein degraders for high genomic instability tumors.